Catalog No.
YHJ15601
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
His1152-Gly1273
Predicted molecular weight
16.61 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
Q86U86
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
PBRM1, Polybromo-1D, hPB1, Protein polybromo-1, BAF180, BRG1-associated factor 180, PB1
Proteomic characteristics of bronchoalveolar lavage fluid in children with mild and severe Mycoplasma pneumoniae pneumonia., PMID:40458711
Polybromo 1/vimentin axis dictates tumor grade, epithelial-mesenchymal transition, and metastasis in pancreatic cancer., PMID:40454484
Switching on the evolutionary potential of pancreatic cancer: the tumor suppressor functions of PBRM1., PMID:40454477
Genetic re-classification of combined hepatocellular-cholangiocarcinoma and small duct type intrahepatic cholangiocarcinoma., PMID:40349569
Impact of mSWI/SNF epigenetic complexes on ionizing radiotherapy resistance in malignant diseases: A comprehensive view in oncology., PMID:40345483
Association of PBRM1 rs2251219 with major depressive disorder and biochemical variables in a Taiwanese cohort., PMID:40340985
Prediction tools for assessing functional impacts of gene mutations in Clear Cell Renal Cell Carcinoma: A comparative study., PMID:40306016
Chromatin remodeling and cancer: the critical influence of the SWI/SNF complex., PMID:40269969
ELOC-Mutated Renal Cell Carcinoma is a Rare Indolent Tumor With Distinctive Genomic Characteristics., PMID:40246078
Insights into the impact of chromosome 3p mutations in advanced renal cell carcinoma treated with immune-based combinations or targeted therapy: A single-center experience., PMID:40233528
Prognostic impact and landscape of cellular CXCR5 chemokine receptor expression in clear-cell renal cell carcinoma., PMID:40208344
Comprehensive Analysis of Roles of APOBEC3 Gene Family in Clear Cell Renal Cell Carcinoma., PMID:40191862
Biomarkers in advanced renal cell carcinoma: current practice and future directions., PMID:40156235
RASSF1A loss in ccRCC: genomic instability and the role of chromosome 3p., PMID:40118587
PBRM1 deficiency enhances PD1 immunotherapeutic sensitivity via chromosomal accessibility in colorectal cancer., PMID:40093909
Optical genome and epigenome mapping of clear cell renal cell carcinoma., PMID:40061565
The prognostic impact of PBRM1 immunohistochemical expression and its association with CD3 + and CD8 + immune cells in patients with renal cell carcinoma: A retrospective study., PMID:40015117
Proteomic analysis reveals chromatin remodeling as a potential therapeutical target in neuroblastoma., PMID:40011918
PBRM1 directs PBAF to pericentromeres and protects centromere integrity., PMID:40011561
A neoantigen vaccine generates antitumour immunity in renal cell carcinoma., PMID:39910301
The value of serum tumor-associated autoantibodies in screening and diagnosis of gastric cancer., PMID:39900126
Deciphering the interplay between SETD2 mediated H3K36me3 and RNA N6-methyladenosine in clear cell renal cell carcinoma (ccRCC)., PMID:39874221
Nanosize Non-Viral Gene Therapy Reverses Senescence Reprograming Driven by PBRM1 Deficiency to Suppress iCCA Progression., PMID:39823528
Clinicopathologic and genomic characteristics of biliary tract carcinomas with TERT promoter mutations among East Asian population., PMID:39793339
Discovery of High-Affinity SMARCA2/4 Bromodomain Ligands and Development of Potent and Exceptionally Selective SMARCA2 PROTAC Degraders., PMID:39745064
Efficacy of glutathione inhibitor eprenetapopt against the vulnerability of glutathione metabolism in SMARCA4-, SMARCB1- and PBRM1-deficient cancer cells., PMID:39732845
Tumor infiltrating T-cells and loss of expression of SWI/SNF genes in varying stages of clear cell renal cell carcinoma., PMID:39693721
CDC20-Mediated Selective Autophagy Degradation of PBRM1 Affects Immunotherapy for Renal Cell Carcinoma., PMID:39656940
Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma., PMID:39672382
Response splicing QTLs in primary human chondrocytes identifies putative osteoarthritis risk genes., PMID:39605710
Understanding the biological processes of kidney carcinogenesis: an integrative multi-omics approach., PMID:39592856
Myoepithelial-Rich Pleomorphic Adenoma With Novel PLAG1 Inversion on Chromosome 8, and LRP1B, PBRM1 and TCF3 Mutations., PMID:39549024
Hepatoid thymic carcinoma in a polycythemia vera patient treated with ropeginterferon Alfa-2b: Clinical, histopathological and molecular correlates., PMID:39405803
Alternative splicing of PBRM1 mediates resistance to PD-1 blockade therapy in renal cancer., PMID:39375538
Toward a CRISPR-based mouse model of Vhl-deficient clear cell kidney cancer: Initial experience and lessons learned., PMID:39365820
Evaluation of PD-L1 expression in PBRM1-altered clear cell renal cell carcinoma., PMID:39341712
Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials., PMID:39313156
Differences in mutations across tumour sizes in clear-cell renal cell carcinoma., PMID:39263870
Targeted therapy with polymeric nanoparticles in PBRM1-mutant biliary tract cancers: Harnessing DNA damage repair mechanisms., PMID:39255911
A Scoping Review of Population Diversity in the Common Genomic Aberrations of Clear Cell Renal Cell Carcinoma., PMID:39250899
A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon/polymerase delta (POLE/POLD1) mutation., PMID:39218995
Prognostic Impact and Genomic Backgrounds of Renal Parenchymal Infiltration or Micronodular Spread in Nonmetastatic Clear Cell Renal Cell Carcinoma., PMID:39142537
Genomic profiles and clinical presentation of chordoma., PMID:39135136
[Clinicopathological features of BAP1 mutated clear cell renal cell carcinoma]., PMID:39103260
The utility of next-generation sequencing in challenging liver FNA biopsies., PMID:39097802
Multifunctional Biomimetic Nanocarriers for Dual-Targeted Immuno-Gene Therapy Against Hepatocellular Carcinoma., PMID:38973319
Screening of reliable reference genes for the normalization of RT-qPCR in chicken oviduct tract., PMID:38959666
BRD7 as key factor in PBAF complex assembly and CD8+ T cell differentiation., PMID:38954484
Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential candidacy for adjuvant immune checkpoint inhibition., PMID:38933491
Multiomics characterization and verification of clear cell renal cell carcinoma molecular subtypes to guide precise chemotherapy and immunotherapy., PMID:38868222
For research use only. Not for human or drug use.
